Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML. Brugts JJ, et al. Among authors: ferrari r. Eur Heart J. 2009 Jun;30(11):1385-94. doi: 10.1093/eurheartj/ehp103. Epub 2009 Apr 4. Eur Heart J. 2009. PMID: 19346520 Free article.
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, Diez J, Drexler H, Ferrari R, Van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Lüscher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. Dzau VJ, et al. Among authors: ferrari r. Cardiovasc Drugs Ther. 2002 Mar;16(2):149-60. doi: 10.1023/a:1015709617405. Cardiovasc Drugs Ther. 2002. PMID: 12090908 Review.
Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K, Ferrari R, Tendera M, Steg PG, Ford I; BEAUTIFUL Steering Committee. Fox K, et al. Among authors: ferrari r. Am Heart J. 2006 Nov;152(5):860-6. doi: 10.1016/j.ahj.2006.01.013. Am Heart J. 2006. PMID: 17070146
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Deckers J, Ferrari R, Remme WJ, Bertrand M, Fox K; EUROPA Trial Investigators. Briggs A, et al. Among authors: ferrari r. Heart. 2007 Sep;93(9):1081-6. doi: 10.1136/hrt.2005.086728. Epub 2006 Nov 29. Heart. 2007. PMID: 17135223 Free PMC article. Clinical Trial.
ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D, Ferrari R; EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. Ceconi C, et al. Among authors: ferrari r. Cardiovasc Res. 2007 Jan 1;73(1):237-46. doi: 10.1016/j.cardiores.2006.10.021. Epub 2006 Nov 10. Cardiovasc Res. 2007. PMID: 17140552 Clinical Trial.
Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study).
Rodriguez-Granillo GA, Vos J, Bruining N, Garcia-Garcia HM, de Winter S, Ligthart JM, Deckers JW, Bertrand M, Simoons ML, Ferrari R, Fox KM, Remme W, De Feyter PJ; Investigators of the EUROPA Study. Rodriguez-Granillo GA, et al. Among authors: ferrari r. Am J Cardiol. 2007 Jul 15;100(2):159-63. doi: 10.1016/j.amjcard.2007.02.073. Epub 2007 May 30. Am J Cardiol. 2007. PMID: 17631061 Clinical Trial.
2,163 results